Classification of frequency of development of side effects of the World
Health Organization (WHO):
Often ≥ 1/10
often from ≥ 1/100 to <1/10
infrequently from ≥ 1/1000 to <1/100
rarely from ≥ 1/10000 to <1/1000
very rarely from <1/10000, including individual messages
frequency is unknown - unwanted reactions with unknown frequency (not can be calculated from available data)
From the nervous system:
often: headache, insomnia, dizziness, paresthesia, asthenic syndrome;
infrequently: peripheral neuropathy, amnesia, hypoesthesia, "nightmarish" dreams;
From the sense organs:
infrequently: noise in the ears;
rarely: nasopharyngitis, epistaxis;
From the cardiovascular system:
palpitation, symptoms of vasodilation, migraine, postural hypotension, increased blood pressure, phlebitis, arrhythmia;
On the part of the hematopoiesis system:
infrequently: thrombocytopenia;
From the respiratory system:
often: chest pain;
From the digestive system:
often: constipation, indigestion, nausea, diarrhea, flatulence (bloating), abdominal pain;
infrequently: a violation of taste perception, vomiting, pancreatitis, belching;
rarely: hepatitis, cholestatic jaundice;
very rarely: liver failure.
From the musculoskeletal system:
often: myalgia, arthralgia, back pain, swelling of the joints;
infrequently: myopathy, muscle cramps;
rarely: myositis, rhabdomyolysis, tendopathy (in some cases with a rupture of tendons);
From the genitourinary system:
often: urinary tract infections;
infrequently: decreased potency, secondary renal failure;
From the skin:
often: skin rash, itchy skin;
infrequently: urticaria, alopecia;
rarely: angioedema, alopecia, bullous rash, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis;
Allergic reactions:
often: allergic reactions;
very rarely: anaphylaxis;
Laboratory indicators:
infrequently: increased activity of aminotransferases (ACT, AJIT), increased serum creatine phosphokinase (CK), leukocyturia;
Very rarely: hyperglycemia, hypoglycemia;
Other:
often: peripheral edema;
infrequently: weakness, fatigue, fever, anorexia,
an increase in body weight, the appearance of "shroud" in front of the eyes.
In the postmarketing use of statins, the following adverse effects were reported: loss or loss of memory, depression, sexual dysfunction, gynecomastia, increased concentration of glycosylated hemoglobin, single cases of interstitial lung disease (especially with prolonged use), cases of immunocompromised necrotic myopathy.
The causal relationship of some unwanted effects with the use of the drug Atorvastatin-SZ, which are regarded as "very rare", is not established.
If severe undesirable effects occur, use of Atorvastatin-C3 should be discontinued.